Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Prurigo nodularis
- Focus Therapeutic Use
- Sponsors Menlo Therapeutics; Tigercat Pharma; Velocity Pharmaceutical Development; VYNE Therapeutics
- 16 Sep 2020 Results evaluating the psychometric properties of the itch numeric rating scale (itch NRS), both the Worst Itch Numeric Rating Scale (WI-NRS) and the Average Itch Numeric Rating Scale (AI-NRS) published in the JAMA Dermatology
- 25 Mar 2019 Results presented in a Menlo Therapeutics media release.
- 17 Mar 2019 Results assessing safety and efficacy of Serlopitant for the treatment of prurigo nodularis published in the Journal of the American Academy of Dermatology